The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Radiation Oncology

Background:

• Oligoprogressive disease (OPD) is defined as disease progression in a limited number of metastatic sites during systemic therapy.
• Emerging evidence supports combining local ablative therapy with systemic agents for improved outcomes in OPD.
• Non-small cell lung cancer (NSCLC) patients with OPD represent a specific population where local control is crucial.

Purpose of the Study:

• To review the current treatment paradigm for patients with oligoprogressive disease.
• To explore the role of local ablative therapy, specifically stereotactic body radiotherapy (SBRT), in managing progressing metastases in NSCLC.
• To provide an updated overview of the existing literature on managing OPD in NSCLC.

Main Methods:

• Literature review of studies investigating oligoprogressive disease in non-small cell lung cancer.
• Analysis of treatment strategies integrating systemic therapy with local ablative approaches.
• Focus on the efficacy and outcomes associated with stereotactic body radiotherapy for selective progressing metastases.

Main Results:

• Local ablative therapy, such as SBRT, shows promise in controlling progressing metastases in OPD.
• Integration of local therapy with systemic agents may lead to improved survival outcomes for NSCLC patients with OPD.
• Selective treatment of progressing lesions can be a viable strategy within a broader treatment plan.

Conclusions:

• Stereotactic body radiotherapy is a key local treatment modality for oligoprogressive non-small cell lung cancer.
• A combined approach of systemic therapy and targeted local ablative treatment is beneficial for selected patients with OPD.
• Further research and clinical trials are warranted to optimize the management of oligoprogressive disease in NSCLC.